S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

MediWound Stock Price, News & Analysis (NASDAQ:MDWD)

$9.10
+0.25 (+2.82%)
(As of 12/4/2023 ET)
Compare
Today's Range
$8.81
$9.10
50-Day Range
$7.58
$10.87
52-Week Range
$7.10
$14.58
Volume
11,733 shs
Average Volume
23,615 shs
Market Capitalization
$83.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

MediWound MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
218.7% Upside
$29.00 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of MediWound in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.96) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

516th out of 952 stocks

Medicinals & Botanicals Industry

4th out of 10 stocks


MDWD stock logo

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

MDWD Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Recap: MediWound Q3 Earnings
MediWound Q3 2023 Earnings Preview
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
MediWound to Report Third Quarter 2023 Financial Results
MediWound Gets CHMP Positive Opinion for NexoBrid
MediWound Ltd MDWD
MediWound Deploys NexoBrid® for Emergency Supply
Maxim Group Sticks to Their Buy Rating for Mediwound (MDWD)
MediWound Announces Full Commercial Launch Of NexoBrid - Quick Facts
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/21/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDWD
Employees
83
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$29.00
High Stock Price Target
$36.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+218.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-19,600,000.00
Pretax Margin
-49.27%

Debt

Sales & Book Value

Annual Sales
$26.50 million
Book Value
$1.51 per share

Miscellaneous

Free Float
8,359,000
Market Cap
$83.81 million
Optionable
Not Optionable
Beta
1.05

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Ofer Gonen B.Sc. (Age 50)
    Chief Executive Officer
    Comp: $485k
  • Dr. Lior Rosenberg M.D. (Age 77)
    Co-Founder
    Comp: $727k
  • Dr. Ety Klinger MBA (Age 61)
    Ph.D., Chief Research & Development Officer
    Comp: $393k
  • Ms. Hani Luxenburg
    Chief Financial Officer
  • Mr. Tzvi Palash B.Sc. (Age 66)
    M.Sc., Chief Operating Officer
  • Mr. Yaron Meyer Adv. (Age 44)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $240k
  • Mr. Barry J. Wolfenson (Age 56)
    Executive Vice President of Strategy & Corporate Development
  • Dr. Robert J. Snyder CWS (Age 73)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer














MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price target for 2024?

4 analysts have issued 1 year target prices for MediWound's stock. Their MDWD share price targets range from $25.00 to $36.00. On average, they expect the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 218.7% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2023?

MediWound's stock was trading at $13.49 at the beginning of 2023. Since then, MDWD shares have decreased by 32.5% and is now trading at $9.10.
View the best growth stocks for 2023 here
.

Are investors shorting MediWound?

MediWound saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 30,200 shares, a decline of 20.9% from the October 31st total of 38,200 shares. Based on an average daily trading volume, of 23,000 shares, the short-interest ratio is presently 1.3 days. Approximately 0.5% of the company's stock are short sold.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings data on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 44.32% and a negative net margin of 49.79%. During the same quarter last year, the firm earned ($0.91) EPS.

When did MediWound's stock split?

MediWound's stock reverse split on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are MediWound's major shareholders?

MediWound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Yelin Lapidot Holdings Management Ltd. (0.94%), Essex Investment Management Co. LLC (0.57%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -